News Sentiment

PMN sentiment intelligence

ProMIS Neurosciences Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 14.25 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+6.7% over one week, +37.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Guggenheim Sticks to Their Buy Rating for ProMIS Neurosciences (PMN)

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 6.7% Price confirming higher
Trend fit Trend inactive 37.7% over four weeks
Fair value -48.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 31
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 8
Market source 7
TradingView 7
TradingKey 5
GlobeNewswire 3
simplywall.st 3
GuruFocus 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 15
Analyst action 7
Capital return 1
Guidance 1
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 47
The Globe and Mail Direct company coverage

Guggenheim Sticks to Their Buy Rating for ProMIS Neurosciences (PMN)

Guggenheim reiterated its "Buy" rating for ProMIS Neurosciences (PMN) with a $35.00 price target, following a previous "Buy" rating from Roth MKM. Despite a quarterly GAAP net loss of $8.24 million, corporate insider sentiment is positive, with increased insider buying, including

Tone
Neutral 50/100
Event
Analyst action
Published
15 Jul 2026 11:41
Source
The Globe and Mail
grafa.com Direct company coverage

ProMIS reports PMN310 oligomer reduction at 29 days

ProMIS Neurosciences reported that its drug candidate PMN310 demonstrated dose-dependent reductions in detectable amyloid-beta oligomers within cerebrospinal fluid three and 29 days after a single dose. This finding provides an exploratory signal that PMN310 reached and engaged i

Tone
Positive 72/100
Event
Market update
Published
14 Jul 2026 11:01
Source
grafa.com
GuruFocus Direct company coverage

ProMIS Neurosciences (PMN) Reports Dose-Dependent Reduction in Amyloid-Beta Oligomers

ProMIS Neurosciences Inc. (PMN) announced promising results from its Phase 1a trial for the Alzheimer's drug candidate PMN310, showing a dose-dependent reduction in amyloid-beta oligomers. Despite strong financial health with no debt, the company faces profitability challenges, r

Tone
Positive 72/100
Event
Earnings
Published
14 Jul 2026 10:40
Source
GuruFocus
GlobeNewswire Direct company coverage

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

ProMIS Neurosciences announced the first human evidence of dose-dependent amyloid-beta oligomer reduction by its Alzheimer's drug candidate, PMN310, at AAIC 2026. The findings from a Phase 1a trial showed a reduction in oligomers in healthy volunteers' cerebrospinal fluid, indica

Tone
Positive 71/100
Event
Analyst action
Published
14 Jul 2026 06:40
Source
GlobeNewswire
Stock Titan Direct company coverage

One Dose of PMN310 Reduced Toxic Amyloid Oligomers in Spinal Fluid

ProMIS Neurosciences announced that its Alzheimer's drug candidate, PMN310, demonstrated a dose-dependent reduction of amyloid-beta oligomers (AβO) in cerebrospinal fluid after a single dose in healthy volunteers. This finding, presented at AAIC 2026, represents a significant mil

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 06:40
Source
Stock Titan
TradingView Direct company coverage

ProMIS Neurosciences Inc. Financial Statements – NASDAQ:PMN

This page provides financial statement information for ProMIS Neurosciences Inc. (NASDAQ:PMN). Key facts like market capitalization, dividend yield, and P/E ratio are currently unavailable, and the company has no history of paying dividends. ProMIS Neurosciences Inc. focuses on d

Tone
Neutral 50/100
Event
Capital return
Published
10 Jul 2026 04:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of ProMIS Neurosciences Inc. – NASDAQ:PMN

The article "Price to sales forward of ProMIS Neurosciences Inc. – NASDAQ:PMN" from TradingView appears to be a stub or a section of a larger financial data page for ProMIS Neurosciences Inc. (PMN). It focuses on the "Price to sales forward" metric, although no specific value is

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 05:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of ProMIS Neurosciences Inc. – NASDAQ:PMN

This article provides a brief mention of the "Enterprise value to revenue forward" metric for ProMIS Neurosciences Inc. (NASDAQ:PMN). It appears to be a financial data point presented on TradingView, likely indicating a valuation ratio for the company. The content itself is very

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 04:12
Source
TradingView
TradingView Direct company coverage

ProMIS Neurosciences Inc. Actuals & Estimates (NASDAQ:PMN)

This article provides an overview of ProMIS Neurosciences Inc. (NASDAQ:PMN) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It details financial actuals and estimates for earnings and revenue, notes the company's next earn

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 19:12
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of ProMIS Neurosciences Inc. – NASDAQ:PMN

This article displays the "Price to earnings forward" metric for ProMIS Neurosciences Inc. (NASDAQ: PMN) on the TradingView platform. The content primarily features navigation elements and data source attributions, with the core financial data point itself being the main focus fo

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 08:11
Source
TradingView
GuruFocus Direct company coverage

PMN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18

HC Wainwright & Co. has reiterated its "Buy" rating for ProMIS Neurosciences (PMN), maintaining a price target of $18.00. While the biotech company, which focuses on neurodegenerative disease therapies, has a strong financial balance sheet (rated 9/10), its GF Score of 32/100 sug

Tone
Positive 64/100
Event
Analyst action
Published
24 Jun 2026 12:40
Source
GuruFocus
Investing.com Direct company coverage

H.C. Wainwright reiterates ProMIS Neurosciences stock rating at buy

H.C. Wainwright has reiterated its Buy rating and $18.00 price target for ProMIS Neurosciences (NASDAQ:PMN), noting the stock's current value of $10.69 represents a significant upside to the target. The firm highlighted ProMIS Neurosciences' plans to develop a subcutaneous formul

Tone
Positive 75/100
Event
Analyst action
Published
23 Jun 2026 19:39
Source
Investing.com
TradingKey Direct company coverage

ProMIS Neurosciences Inc (PMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of ProMIS Neurosciences Inc (PMN), detailing its current price momentum score, support and resistance levels, and an evaluation based on various technical indicators and moving averages. According to the analysis, PMN is currently suitab

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 00:09
Source
TradingKey
TradingKey Direct company coverage

ProMIS Neurosciences Inc (PMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for ProMIS Neurosciences Inc (PMN), detailing its business segments, regional revenue, and profit contribution. As of March 4, 2025, the company has not disclosed relevant data for FY2019 and FY2020. The only regional revenue data availab

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 17:40
Source
TradingKey
TradingKey Direct company coverage

ProMIS Neurosciences Inc (PMN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of ProMIS Neurosciences Inc (PMN), listing major shareholders and their proportions, as well as a breakdown by shareholder type. It also provides institutional shareholding data from Q1 2023 to Q1 2026, showing changes in the number

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 17:40
Source
TradingKey
TradingKey Direct company coverage

ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for ProMIS Neurosciences Inc (PMN), highlighting its current earnings forecast score of 8.40 and an average price target of $112.50 from 5 analysts, with most recommending a "Buy" trend. It details the company's recent EPS performance, w

Tone
Positive 69/100
Event
Earnings
Published
17 Jun 2026 11:39
Source
TradingKey
TradingKey Direct company coverage

ProMIS Neurosciences Inc (PMN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for ProMIS Neurosciences Inc (PMN), noting its current valuation score of 6.70 within the Biotechnology & Medical Research industry. It highlights the company's negative P/E ratio, indicating a loss, and states that relevant data for P/B

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 23:10
Source
TradingKey
Investing.com Canada Direct company coverage

H.C. Wainwright reiterates Buy on ProMIS Neurosciences stock By Investing.com

H.C. Wainwright has reiterated a Buy rating and an $18.00 price target for ProMIS Neurosciences (NASDAQ:PMN). The company's stock is currently trading at $9.71, and InvestingPro analysis suggests it is undervalued. ProMIS Neurosciences is nearing key milestones for its Phase 1b t

Tone
Neutral 50/100
Event
Analyst action
Published
09 Jun 2026 11:39
Source
Investing.com Canada
GlobeNewswire Direct company coverage

ProMIS Neurosciences to Participate in Upcoming Conferences in June

ProMIS Neurosciences Inc. announced its participation in several healthcare conferences in June 2026, including the Jefferies Global Healthcare Conference and BIO International Convention. CEO Neil Warma will discuss the company's EpiSelect™ platform and its lead Alzheimer's dise

Tone
Positive 66/100
Event
Market update
Published
28 May 2026 14:39
Source
GlobeNewswire
Stock Titan Direct company coverage

Alzheimer’s drug trial data from ProMIS expected in early Q3 2026

ProMIS Neurosciences (Nasdaq: PMN) announced it will participate in several healthcare and biotech conferences in June 2026 to discuss its EpiSelect™ platform and lead Alzheimer’s candidate PMN310. The company expects to report blinded 6-month interim data from its PRECISE-AD Pha

Tone
Positive 64/100
Event
Guidance
Published
28 May 2026 14:08
Source
Stock Titan
Stock Titan Direct company coverage

ProMIS Neurosciences (NASDAQ: PMN) shareholders approve larger 2025 stock option plan

ProMIS Neurosciences shareholders approved an amendment to the 2025 Stock Option and Incentive Plan, increasing the shares available for issuance by 900,000 Common Shares. The approval occurred at the company's 2026 annual meeting where shareholders also elected seven director no

Tone
Neutral 50/100
Event
Regulatory and legal
Published
23 May 2026 14:39
Source
Stock Titan